Sanofi (SNY)

41.33
0.82 1.95
NASDAQ : Health Technology
Prev Close 42.15
Open 41.60
Day Low/High 41.26 / 41.67
52 Wk Low/High 37.43 / 45.62
Volume 1.33M
Avg Volume 893.80K
Exchange NASDAQ
Shares Outstanding 2.58B
Market Cap 105.57B
EPS 2.00
P/E Ratio 22.70
Div & Yield 1.20 (2.94%)

Latest News

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Monday.

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

The charges were related to an interest-rate problem.

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

Government Shutdown and Everything Else You Need to Know Monday Morning

Government Shutdown and Everything Else You Need to Know Monday Morning

So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.

Winners and Losers in a Temporary French Tax Revolution

Winners and Losers in a Temporary French Tax Revolution

Some French companies will get a temporary windfall, but others will need to pay more tax.

These 16 Stocks Look Ready to Reverse

These 16 Stocks Look Ready to Reverse

Tesla and General Motors are among this week's names showing reversal patterns.

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Investors keep an eye on another busy slate of earnings.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Shark Tank's Robert Herjavec on why the Equifax hack is different from others cyber attacks.

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Mailbag: Buy Dip in T2 Biosystems?

Plus, what's going on with Lexicon Pharmaceuticals?

Sanofi Has Good Potential Upside

Sanofi Has Good Potential Upside

I would buy strength above $50 and $51 in Sanofi.

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

HSBC Security Downgrades Sanofi

HSBC Security Downgrades Sanofi

The stock was trading slightly lower this afternoon.

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

Las Vegas Sands and Flexion are in, and the autos are out.

Sanofi to Pay for Drug Overcharges

Sanofi to Pay for Drug Overcharges

Sanofi SA agreed to a U.S. Department of Justice a $19.8 million fine for overcharging the U.S. Department of Veteran Affairs.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

15 Remakes and Sequels Coming to the Silver Screen in 2017

15 Remakes and Sequels Coming to the Silver Screen in 2017

Hollywood's lack of originality shines through with 15 remakes and sequels this year.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Sanofi's Base Pattern Should Make Investors Happy

Sanofi's Base Pattern Should Make Investors Happy

SNY has become much stronger since late October; buy here and above $44.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.